expand_moreexpand_less
Aeon
Al Jazeera
América Economía
Blitz
Buenos Aires Herald
Deutsche Welle
Dnevnik
E-International
Haaretz
Il Manifesto Global
Japan Today
Khaama PressMiddle East Monitor
New Eastern OutlookNikkei Asian ReviewOped Column
Pravda.sk
Project Syndicate
Psychology TodayRT.comSME.sk
South China Morning PostThe Asahi ShimbunThe Japan NewsThe Japan Times
The Korea TimesThe Times of IsraelThe Times of Israel (Blogs)
TRT WorldVečer
العين الإخبارية 
Toi StaffEmanuel FabianJacob MagidAgenciesLuke TressReutersSam SokolNava FreibergJeremy SharonAmanda Borschel-DanZev StubRossella TercatinLazar BermanCharlie SummersStav LevatonMatthew Ward AgiusAmy SpiroNurit Yohanan
Belen Fernandez
Gideon LevySumaya MohammedEhud OlmertThe Japan News EditorialSharon WrobelGrace Gilson
Jeffrey Bernstein Ph.d
Tarik Cyril Amar
Rachel MarsdenBen SalesVesna V. GodinaPeter BaumMartina SchwikowskiRich TenorioMichael BachnerAluf BennStephanie HöppnerEnno HinzFred Schwaller
Omar MohammedDr Binoy KampmarkTommy WalkerNoam LehmannTatjana PihlarKate Hairsine
Muhannad AyyashCathrin SchaerOliver PieperDiana BletterLeon Garber LmhcNicolas Martin
|
 |
Steve MacfarlaneThe Conversation |
Donanemab is only for use in the early stages of Alzheimer’s disease. And for now at least, it comes with a hefty price tag.
A Korean study published recently suggests people with type 2 diabetes who are prescribed a particular class of drug might be at a significantly...
login
who are we?
contact us
qosheapp
